INBRX-130 / Inhibrx Biosci - LARVOL DELTA

INBRX-130, a 5T4-targeted CONTRA-MAB, is a potent CD3 bispecific antibody engineered to have minimal off-tumor activity (AACR 2022) - "CONTRA-MABs® have the potential to have enhanced accumulation in solid tumors relative to other CD3 bispecific antibodies as a result of reduced systemic engagement of T cells and increased tolerability at high doses. These attributes, coupled with the broad tumor biased expression of 5T4 across solid tumors, may enable INBRX-130 to have a greater therapeutic index and provide a significant benefit to patients in need."

Hematological Malignancies • Oncology • Solid Tumor • TPBG

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting (PRNewswire) - "Inhibrx...announced today that data from INBRX-121 and INBRX-130 will be presented at the 2022 American Association for Cancer Research ('AACR') Annual Meeting...'We are excited to share some of the updated preclinical data for our targeted cytokine platform and INBRX-121 that specifically expands and enhances the cytotoxic capacity of NK cells. Additionally, we will introduce our unique T-cell engager platform, CONTRA-MAB®, and INBRX-130 that targets the 5T4 antigen on solid tumors'..."

Preclinical • Oncology • Solid Tumor